Literature DB >> 24074852

Psychometric properties of the adjective rating scale for withdrawal across treatment groups, gender, and over time.

Celestina Barbosa-Leiker1, Sterling McPherson, Mary Rose Mamey, G Leonard Burns, John Roll.   

Abstract

The adjective rating scale for withdrawal (ARSW) is commonly used to assess opiate withdrawal in clinical practice and research. The aims of this study were to examine the factor structure of the ARSW, test measurement invariance across gender and treatment groups, and assess longitudinal measurement invariance across the clinical trial. Secondary data analysis of the National Drug Abuse Treatment Clinical Trials Network 000-3, a randomized clinical trial comparing two tapering strategies, was performed. The ARSW was analyzed at baseline, end of taper and 1-month follow-up (N=515 opioid-dependent individuals). A 1-factor model of the ARSW fit the data and demonstrated acceptable reliability. Measurement invariance was supported across gender and taper groups. Longitudinal measurement invariance was not found across the course of the trial, with baseline assessment contributing to the lack of invariance. If change over time is of interest, change from post-treatment through follow-up may offer the most valid comparison.
© 2013.

Entities:  

Keywords:  Measurement invariance; Opiate dependence; Opiate withdrawal; Psychometrics

Mesh:

Substances:

Year:  2013        PMID: 24074852      PMCID: PMC3870009          DOI: 10.1016/j.jsat.2013.08.020

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  12 in total

1.  Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Authors:  L Amass; J B Kamien; S K Mikulich
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  A practical and theoretical guide to measurement invariance in aging research.

Authors:  J L Horn; J J McArdle
Journal:  Exp Aging Res       Date:  1992 Autumn-Winter       Impact factor: 1.645

3.  Assessing and understanding measurement equivalence in health outcome measures. Issues for further quantitative and qualitative inquiry.

Authors:  Colleen A McHorney; John A Fleishman
Journal:  Med Care       Date:  2006-11       Impact factor: 2.983

4.  Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Authors:  Douglas M Ziedonis; Leslie Amass; Marc Steinberg; George Woody; Jonathan Krejci; Jeffrey J Annon; Allan J Cohen; Nancy Waite-O'Brien; Susan M Stine; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Robert Maslansky; Theresa Winhusen; Dean Babcock; Greg Brigham; Joan Muir; Deborah Orr; Betty J Buchan; Terry Horton; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2008-09-20       Impact factor: 4.492

5.  A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Authors:  Walter Ling; Leslie Amass; Steve Shoptaw; Jeffrey J Annon; Maureen Hillhouse; Dean Babcock; Greg Brigham; Judy Harrer; Malcolm Reid; Joan Muir; Betty Buchan; Debbie Orr; George Woody; Jonathan Krejci; Douglas Ziedonis
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

6.  Buprenorphine tapering schedule and illicit opioid use.

Authors:  Walter Ling; Maureen Hillhouse; Catherine Domier; Geetha Doraimani; Jeremy Hunter; Christie Thomas; Jessica Jenkins; Albert Hasson; Jeffrey Annon; Andrew Saxon; Jeffrey Selzer; Joshua Boverman; Richard Bilangi
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

7.  Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Authors:  Leslie Amass; Walter Ling; Thomas E Freese; Chris Reiber; Jeffrey J Annon; Allan J Cohen; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Cynthia Clark; Douglas M Ziedonis; Jonathan Krejci; Susan Stine; Theresa Winhusen; Greg Brigham; Dean Babcock; Joan A Muir; Betty J Buchan; Terry Horton
Journal:  Am J Addict       Date:  2004

8.  A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

Review 9.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

10.  Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

View more
  3 in total

1.  Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003.

Authors:  Celestina Barbosa-Leiker; Sterling McPherson; Mary Rose Mamey; G Leonard Burns; Matthew E Layton; John Roll; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2015-04-11       Impact factor: 4.492

2.  Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.

Authors:  Celestina Barbosa-Leiker; Sterling McPherson; Matthew E Layton; Ekaterina Burduli; John M Roll; Walter Ling
Journal:  Am J Drug Alcohol Abuse       Date:  2018-04-19       Impact factor: 3.829

3.  Testing for response shift in treatment evaluation of change in self-reported psychopathology amongst secondary psychiatric care outpatients.

Authors:  Ingrid V E Carlier; Wessel A van Eeden; Kim de Jong; Erik J Giltay; Martijn S van Noorden; Christina van der Feltz-Cornelis; Frans G Zitman; Henk Kelderman; Albert M van Hemert
Journal:  Int J Methods Psychiatr Res       Date:  2019-06-17       Impact factor: 4.035

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.